- Home
- CSAN vs APGE Comparison
CSAN vs APGE Comparison
Compare CSAN & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSAN | APGE |
|---|---|---|
| Founded | 1936 | 2022 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.7B |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CSAN | APGE |
|---|---|---|
| Price | $4.42 | $86.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $4.75 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $321.51 | N/A |
| Revenue Next Year | $3.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $31.21 |
| 52 Week High | $6.25 | $87.00 |
Technical Indicators
Market Signals| Indicator | CSAN | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 66.36 |
| Support Level | $4.17 | $73.06 |
| Resistance Level | $4.74 | N/A |
| Average True Range (ATR) | 0.17 | 4.44 |
| MACD | 0.06 | 0.76 |
| Stochastic Oscillator | 87.41 | 89.83 |
Price Performance
Historical ComparisonAbout CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.